Zepbound Outperforms Wegovy in Weight Loss Trial, Reports Eli Lilly
TL;DR Summary
Eli Lilly's Zepbound has shown promising results in preliminary research, indicating it may help patients lose more weight than Novo Nordisk's Wegovy over 72 weeks. Zepbound, containing tirzepatide, reportedly aids weight loss by mimicking gut hormones that signal fullness. Users like Barbara Strecker-Gaudreau and her daughter Alexis have experienced significant weight loss with Zepbound, alongside lifestyle changes. While Novo Nordisk highlights Wegovy's cardiovascular benefits, both medications have side effects such as nausea and require lifestyle interventions for optimal results.
- Zepbound users discuss weight loss after preliminary research touts effectiveness ABC News
- Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Investors | Eli Lilly and Company
- Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial CNBC
- Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial BioPharma Dive
- Zepbound More Effective Than Wegovy for Weight Loss, Eli Lilly Says Healthline
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 3 min read
Condensed
87%
598 → 79 words
Want the full story? Read the original article
Read on ABC News